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Epidermal growth factor receptor (EGFR) mutations are strong determinants of tumour response to EGFR tyrosine kinase inhibitors in
non-small-cell lung cancer (NSCLC). Pleural effusion is a common complication of lung cancer. In this study, we assessed the feasibility
of detection of EGFR mutations in samples of pleural effusion fluid. We obtained 43 samples, which was the cell-free supernatant of
pleural fluid, from Japanese NSCLC patients, and examined them for EGFR mutations. The epidermal growth factor receptor mutation
status was determined by a direct sequencing method (exons 18–21 in EGFR). EGFR mutations were detected in 11 cases
(E746_A750del in seven cases, E746_T751del insA in one case, L747_T751del in one case, and L858R in two cases). The EGFR
mutations were observed more frequently in women and non-smokers. A comparison between the EGFR mutant status and the
response to gefitinib in the 27 patients who received gefitinib revealed that all seven patients with partial response and one of the
seven patients with stable disease had an EGFR mutation. No EGFR mutations were detected in the patients with progressive disease.
The results suggest that DNA in pleural effusion fluid can be used to detect EGFR mutations and that the EGFR mutation status may
be useful as a predictor of the response to gefitinib.
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Lung cancer is a major cause of cancer-related mortality worldwide
and is expected to remain a major health problem for the
foreseeable future (Parkin et al, 2005). Most patients have
advanced disease at the time of diagnosis. The initial therapy for
advanced non-small-cell lung cancer (NSCLC) is systemic chemo-
therapy with a two-drug combination regimen, which often
includes a platinum agent, but the median survival of patients
treated with such regimens has ranged from only 8 to 10 months.
Little improvement in the efficacy of chemotherapy has been made
in the last 20 years (Breathnach et al, 2001; Kelly et al, 2001;
Schiller et al, 2002).
Targeting epidermal growth factor receptor (EGFR) is an
appealing strategy for the treatment of NSCLC, because EGFR
has been found to be expressed, sometimes strongly, in NSCLC
(Franklin et al, 2002). Gefitinib (‘Iressa’, AstraZeneca) is a small
molecule and selective EGFR tyrosine kinase inhibitor that has
shown antitumour activity in NSCLC patients as a single agent in
phase II trials (Fukuoka et al, 2003). Adding gefitinib to
chemotherapy in phase III studies of patients with untreated
advanced NSCLC did not significantly improve the outcome over
chemotherapy alone (Giaccone et al, 2004; Herbst et al, 2004), and
a possible explanation for the failure to observe any added benefit
in these trials is that the patients had not been screened or selected
for their ability to derive any clinical benefit from an EGFR
inhibitor.
An association between mutations in sites of EGFR tyrosine
kinase in NSCLC and hyper-responsiveness to gefitinib has
recently been reported (Lynch et al, 2004; Paez et al, 2004). The
mutations consisted of small in-frame deletions or substitutions
clustered around the ATP-binding site in exons 18, 19, and 21 of
EGFR, and the mutations increased the affinity of the enzyme for
ATP and gefitinib (Lynch et al, 2004). Some investigators
subsequently found that EGFR mutations are one of the strong
determinants of tumour response to EGFR tyrosine kinase
inhibitors (Pao et al, 2004; Han et al, 2005). The investigators
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sused surgical tissue to detect the EGFR mutations in their studies,
but most patients who require gefitinib therapy are diagnosed at
an advanced stage of the disease and are inoperable. As it is often
difficult to obtain a sufficient tumour sample from patients with
inoperable NSCLC to detect EGFR mutations by direct sequencing,
a method of detecting EGFR mutations in other specimens needed
to be established.
Malignant pleural effusion is a common complication of lung
cancer. It is present in approximately 15% of patients at the time of
diagnosis (Pass et al, 2005) and in 10–50% of patients during the
course of the disease (Fenton and David Richardson, 1995).
In about half of NSCLC patients with a pleural effusion,
the effusion fluid is cytologically positive at the first time
examined, and ultimately most effusions are determined to be
malignant. As pleural effusion fluid sampling is usually easy, non-
invasive, and repeatable, we hypothesised that tumour-derived
DNA in the pleural effusion fluid of NSCLC patients would be a
source of useful information on the status of the EGFR gene and
could allow prediction of the response to gefitinib. Some
investigators have reported that pleural effusion fluid is a useful
clinical specimen for searching for point mutations in oncogenes,
such as K-ras, rho A, p53, and FHIT (Nakamoto et al, 2001;
Lee et al, 2004). As the two trials were small, the results regarding
the sensitivity and specificity of detection of the mutations in
pleural effusion as a diagnostic method were unclear. Detection
of EGFR mutations in pleural effusion fluid has been described in
one case report, and the patient responded to gefitinib (Huang
et al, 2005). The results in that patient encouraged us to
hypothesise that the EGFR mutation status determined in pleural
effusion fluid is useful for predicting the responsiveness to EGFR
tyrosine kinase inhibitors.
In the present study, we attempted to detect EGFR mutations in
pleural effusion fluid and to clarify the usefulness of their detection
as a predictor of the response to gefitinib.
PATIENTS AND METHODS
Patients
The subjects were NSCLC patients who had a pleural effusion
at the time of diagnosis. The diagnosis of NSCLC was based
on the histological or cytological findings, and the histological
type was determined according to the WHO criteria (Travis
et al, 1999). Patients’ records consisted of age, gender, smoking
habit, histological type, and treatment. Smoking status was
collected from the patients’ records. Patients were divided into
three groups according to their smoking status: never smokers
(o100 cigarettes/lifetime), former smokers (X100 cigarettes/
lifetime, no smoking at present), and current smokers (X100
cigarettes/lifetime). The response of the patients treated with
gefitinib was evaluated every 4 or 8 weeks in accordance with
the ‘Response Evaluation Criteria in Solid Tumours (RECIST)’
guidelines. (Therasse et al, 2000). Partial response (PR) and
stable disease (SD) were confirmed by a sustained 4-week
follow-up. This study was approved by the Institutional Review
Board of the National Cancer Center Hospital and of Kanazawa
University Hospital, and written informed consent was obtained
from all participants. No research results were entered into the
patient’s records or released to the patient or the patient’s
physician.
Collection of pleural effusion fluid and DNA purification
The pleural effusion fluid was collected into heparinised tubes
between 29 March 2005 and 30 January 2006. No particular
collection method was used. A 2-ml sample of the fluid was
centrifuged at 250g for 10min at room temperature, and the
supernatant was collected and stored at  801C until DNA
extraction. DNA was extracted from 1ml of the supernatant with
a Qiamp DNA Mini Kit (Qiagen, Hilden, Germany) according to
the blood and body fluid spin protocol in the manufacturer’s
instructions, with the following protocol modifications. The same
column was used repeatedly until the whole sample had been
processed. The DNA obtained was eluted in 50ml of sterile bi-
distilled buffer, and the extracted DNA was stored at  201C until
used. The amounts of DNA extracted were estimated with
spectrophotometry.
Polymerase chain reaction amplification and direct
sequencing
Exons 18, 19, 20, and 21 of the EGFR gene were amplified by
polymerase chain reaction (PCR). The primers were designed
based on the report by Lynch et al (2004). Genomic PCR of 1ml
of template DNA was performed in 25ml volumes containing
0.75U of Ampli Taq Gold DNA polymerase (Perkin-Elmer,
Roche Molecular Systems Inc., Branchburg, NJ, USA), 2.5mlo f
PCR buffer, 0.8mM dNTP, 0.5mM of each primer, and different
concentrations of MgCl2, depending on the polymorphic
marker. The first PCR analyses were performed in a volume of
25ml by 25 cycles consisting of a denaturation step at 941C for
45s, a primer annealing step at 581C for 30s, and an elongation
step at 721C for 30s. The final step at 721C was extended
for 10min. Nested PCR was performed with 20 cycles under
the same conditions as the first PCR. Sequencing of each sample
was performed in duplicate with an ABI prism 310 (Applied
Biosystems, Foster City, CA, USA). PCR products were sequenced
in both sense and antisense directions. Epidermal growth
factor receptor mutations detected in the initial round of
sequencing were confirmed by subsequent rounds of independent
PCR and sequencing reactions. Only specimens in which a
mutation was identified in both rounds were recorded as
mutation-positive. The sequences were compared with the
GenBank-archived human sequence for EGFR (accession number:
AY588246). The nucleic acid and protein coordinates used to name
the mutations are based on NM_005228.3 and NP_005219.2,
respectively.
Statistical analyses
This study was carried out as exploratory research for detecting
EGFR mutations from pleural effusion fluid and clarifying the
relationship between the mutation status and clinical manifesta-
tions. The number of enrolled patients was therefore not
precalculated. Patient characteristics, including gender, tumour
histology, and smoking habit were tabulated according to their
mutation status. Fisher’s exact test was used to test for associations
between the presence of EGFR mutations and the patients’
characteristics. The relationship between response to gefitinib
and the mutation status was evaluated individually.
RESULTS
Patients and pleural effusion specimens
Forty-three patients were enrolled in this study (Table 1).
Two hundred and sixty-two patients were seen with stage
IIIB and IV at our institutions in the period of this study.
Forty-three of the 262 patients were enrolled in this study. The
enrolled patients were not all of the patients with pleural effusion
because written informed consent was not obtained from any
patients with pleural effusion. Their median age was 62 years
(range, 39–82 years), and there were 21 females (53.8%) and 17
never smokers (43.6%). The histological and/or cytological
diagnosis was adenocarcinoma in 39 patients, and squamous cell
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scarcinoma and large cell carcinoma in one each, and unclassified
NSCLC in two patients. Non-small-cell lung cancer cells in the
pleural effusion samples of 40 of the patients were identified
cytologically. There were no malignant cells in the pleural effusion
fluid of the other three patients. We have no data of the proportion
of malignant cells and normal cells. Twenty-seven patients were
treated with gefitinib (250mgday
 1) and evaluated for a response.
Eight of the 27 patients were treated with gefitinib as an initial
treatment and the other 19 patients were treated with the agent as a
second or third line. The others were treated with systematic
chemotherapy, including a platinum agent. The results of the
evaluation showed that seven of the 27 patients who received
gefitinib therapy had a PR and seven had SD. The other 13 patients
had progressive disease (PD). DNA was extracted from all 43
samples of pleural effusion fluid. Amounts of the DNA extracted
were detectable from 27 samples at a concentration up to
144.0ngml
 1. Amounts from 16 samples were under the detectable
limit.
Detection of EGFR mutations in pleural effusion fluid
Direct sequencing of PCR products in exons 18–21 of EGFR
in the pleural effusion fluid of all patients allowed their
mutation status to be determined. Heterozygous mutations were
identified in 11 (25.6%) of the 43 patients (Table 1). Nine
mutations were deletional mutations located in exon 19
(E746_A750del in seven, L746_T751del insA in one, L747_T751del
in one), and two were substitution mutations located in exon
21 (L858R) (Table 2) (Figure 1). No mutations were detected
in exon 18 or 20. The E746_A750 deletion and L858R substitu-
tion mutations were the most common (9 out of 11 mutations.
81.8%) and are well-known hotspot mutations described
previously (Kosaka et al, 2004; Pao et al, 2004). No more than
one mutation was identified per patient, and no EGFR mutations
were detected in pleural effusion fluid that did not contain
malignant cells.
Epidermal growth factor receptor mutation status and
patients’ characteristics
EGFR mutations were detected more frequently in the samples
from females (7 out of 21, 33.3% of females, 4 out of 18, 22.2% of
males; P¼0.310) and non-smokers (7 out of 17, 41.1% of non-
smokers, 4 out of 22, 18.1% of current or former smokers;
P¼0.156), although the differences were not statistically signifi-
cant (Table 3). Of the 11 mutations, 63.6% were in women and
63.6% were in non-smokers. All of the patients with mutations had
adenocarcinoma. No EGFR mutations were found in any of the
patients with squamous carcinoma or large cell carcinoma. A
comparison between the EGFR mutant status and the response to
gefitinib showed that all seven patients with a PR and one of the
seven patients with SD had an EGFR mutation. No EGFR
mutations were detected in any of the patients with PD (Table 4).
We have no response data from the 16 patients who had never
treated with gefitinib, and we have not evaluated the relationship
between the response to chemotherapy and the EGFR mutation
status in pleural effusion fluid.
DISCUSSION
This is the first report of an analysis of the EGFR mutation status
in DNA obtained from the pleural effusion fluid of a series of
NSCLC patients and evaluation of the relationship between the
mutation status and the clinical response to gefitinib. It is
interesting that all patients who achieved a PR to gefitinib had
the EGFR mutations. We hypothesised that the mutation status in
DNA extracted from pleural effusion fluid would allow prediction
of the clinical outcome of gefitinib therapy in NSCLC patients, and
we therefore expected the pleural effusion fluid to be a practical
source of DNA for detection of EGFR mutations. The sites of EGFR
mutations found in this study are identical to these reported in
previous studies (Kosaka et al, 2004; Pao et al, 2004). The main
mutations found were in-frame deletions in exon 19 and the
missense mutation L858R in exon 21. No patients had more than
one mutation. It was possible to determine the mutation status of
EGFR by using the DNA in only 1.0ml of pleural effusion fluid,
even though the concentration of the extracted DNA specimens
was in most cases below the concentration detectable by spectro-
photometry (data not shown). The results of the comparison
between the mutation status and clinical manifestations in this
study confirmed the finding in previous studies that EGFR
mutations are frequently present in small sub-groups of NSCLC
patients, such as females and never smokers, although the
differences were not statistically significant. It is well known that
EGFR mutations are frequently observed in adenocarcinomas. As
36 of the 39 patients (92.3%) enrolled in this study had
adenocarcinoma, we could not evaluate differences in the
frequency of the EGFR mutations according to the histological
type. Pleural effusion occurs in lung carcinoma of all cell types, but
Table 1 Patient characteristics and EGFR mutation status
EGFR mutation
(n) (n)





Male 22 4 (18.2%)
Female 21 7 (33.3%)
Smoking habit
Current 9 2 (22.2%)
Former 16 2 (12.5%)
Never 18 7 (38.9%)
Histology
Adenocarcinoma 39 11 (28.2%)
Squamous cell carcinoma 1 0 (0%)
Large cell carcinoma 1 0 (0%)
Unclassified 2 0 (0%)
No. of patients treated with gefitinib 27 8 (29.6%)
PR 7 7 (14.3%)
SD 7 1 (0%)
PD 13 0 (0%)
EGFR¼epidermal growth factor receptor; PD¼progressive disease; PR¼partial
response; SD¼stable disease.
Table 2 Site of mutations in exons 18–21 of EGFR
Nucleotide changes Amino-acid changes No. of patients
2481_2495del E746_A750del 6
2482_2496del E746_A750del 1
2483_2497del E746_T753del insA 1
2486_2500del L747_T751del 1
2819T4G L858R 2
EGFR¼epidermal growth factor receptor; del¼deletion; ins¼insertion. The
numbering of the mutation sites was based on NM_005228.3 (nucleotide) and
NP_005219.2 (amino acid).
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sappears to be most frequent in adenocarcinoma (Chernow and
Shahn, 1997).
This study had several limitations. First, we could not compare
the results of the EGFR mutation status in the pleural effusion fluid
to the mutation status in tumour tissue. Forty of the 43 patients
enrolled were cytologically diagnosed as having NSCLC from
pleural effusion fluid specimens. As the DNA extracted from
pleural effusion fluid consisted of DNA derived from both tumour
cells and normal cells, the EGFR mutation status needs to be






Figure 1 The wave figures of the nucleotide sequence of the EGFR gene with heterozygous mutations obtained by direct sequencing (see ‘Patients and
Methods’) are shown. Horizontal arrows in both the sense and the antisense directions are shown to demonstrate the two breakpoints of the deletion. The
patients in A, B, and C have inframe deletions in exon 19 (Figure A, E746_A750del; B, E746_T753del insA; C, L747_T751del; D, L858R). The double
peaks (vertical arrows) represent the heterozygous missense mutations resulting in an amino acid substitution of L858R in exon 19 (Figure D).
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seffusion fluid to confirm the usefulness of the mutation status
determined from pleural effusion fluid. However, it is sometimes
difficult to obtain tumour samples from patients with advanced
NSCLC, and even more so from patients diagnosed as having
NSCLC using methods other than the histological examination
of tumour tissue, such as on the basis of pleural effusion or
sputum cytology. Second, direct sequencing may be not able to
provide satisfactory results for detection of EGFR mutations in
mixed samples of mutated and wild DNA. Although direct
sequencing has generally been used to detect EGFR mutations in
previous studies, detection of a mutation by this method requires
at least 30% of the mutated DNA in a sample (Bosari et al, 1995;
Fan et al, 2001). Lung cancers are very heterogeneous, and as
normal cells, such as inflammatory cells or mesothelial cells, are
contained in the pleural effusion fluid of lung cancer patients, in
addition to tumour cells, a small amount of mutated DNA in
pleural effusion fluid can be missed by direct sequencing.
Unfortunately, we have no data at the present time on whether
EGFR mutations were detectable in pleural effusion samples with
either a few malignant cells, a small proportion of malignant cells
with normal mesothelial cells, or cytologically negative samples. To
establish a method for the detection of EGFR mutations from
pleural effusion fluid, the mutation detectable proportion of
malignant cells to normal cells in pleural fluid should be
elucidated. We are planning an additional study using cytological
examination to clarify the mutation detectable proportion as a next
step. When pleural fluid is used as the material for detection of
EGFR mutations, a patient with an EGFR mutation may be
diagnosed as having wild-type EGFR because of the two limitations
described above. Although we expected a high frequency of
detection of EGFR mutations in this study because of the high
proportion of adenocarcinomas (92.3%), we detected EGFR
mutations in only 28.2% of the patients enrolled, a lower frequency
than in two previous reports on Japanese NSCLC patients (Takano
et al, 2005; Asano et al, 2006). Patients with false-negative results,
meaning that no EGFR mutations were detected in a patient with
an EGFR mutation, were not excluded from this study. Some
investigators have tried to improve the sensitivity of detection of
EGFR mutations in samples containing a mixture of tumour and
normal cells. Wookey et al (2005) reported findings that the ARMS
method was superior to the direct sequencing method and WAVE
method for detecting EGFR mutations. Other groups have reported
that LightCycler PCR assay (Sasaki et al, 2005), SSCP assay
(Marchetti et al, 2005), and enriched PCR assay (Asano et al) are
more sensitive than direct sequencing and are more rapid. A
standardised method of detecting EGFR mutations needs to be
established as soon as possible.
The final limitation in the present study is that it remains
unclear whether there is any survival benefits associated with
gefitinib therapy in those patients enrolled with EGFR mutations.
The relationship between the EGFR mutation status determined in
pleural effusion fluid and the gefitinib response in a portion of the
patients enrolled supports the pleural effusion fluid EGFR
mutation status as useful for predicting the response to gefitinib.
The relationship between the EGFR mutation status determined in
the pleural effusion fluid and the gefitinib response in the
remaining patients and the survival benefit of gefitinib therapy
in the patients with EGFR mutations are currently being evaluated,
and confirmation of the results is expected in the very near future.
In conclusion, our results suggest that the DNA in pleural
effusion fluid can be used to detect EGFR mutations and that the
EGFR mutation status determined may be useful as a predictive
factor of response to gefitinib.
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Table 4 EGFR mutation status in patients who received gefitinib therapy
Age






62 F Never Ad E747_P753insS PR
58 F Never Ad E746_A750del PR
80 F Never Ad E746_A750del PR
61 M Never Ad E746_A750del PR
65 M Former Ad E746_A750del PR
60 M Current Ad E746_A750del PR
66 F Never Ad E747_T750del PR
76 F Never Ad Wild SD
57 F Former Ad Wild SD
40 F Never Ad Wild SD
72 F Never Ad Wild SD
58 F Former Ad Wild SD
66 F Never Ad Wild SD
65 F Former Ad L858R SD
39 F Never Ad Wild PD
69 M Former Ad Wild PD
72 F Never Ad Wild PD
74 F Never Ad Wild PD
67 M Former Ad Wild PD
62 M Former SCC Wild PD
59 F Current Ad Wild PD
77 M Current Ad Wild PD
82 F Never Ad Wild PD
66 F Never Ad Wild PD
56 M Current Ad Wild PD
61 M Former Ad Wild PD
65 M Former Ad Wild PD
Ad¼adenocarcinoma; EGFR¼epidermal growth factor receptor; F¼female;
M¼male; NSCLC¼unclassified NSCLC; PD¼progressive disease; PR¼partial
response; SCC¼squamous cell carcinoma; SD¼stable disease.
Table 3 Frequency of EGFR mutations in DNA from the pleural effusion
fluid of NSCLC patients according to (A) gender, (B) histology, (C) smoking
habit, and (D) response to gefitinib




Male 4 18 P¼0.310




Non-Ad 0 4 P¼0.558




Current/former 4 21 P¼0.156
Ad¼adenocarcinoma; EGFR¼epidermal growth factor receptor; +¼mutation-
positive;  ¼no mutations. (A)(B)(C); a total of 43 samples were evaluated.
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